^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    ABM-3249

    i
    Other names: ABM-3249
    Associations

    News

    Trials
    Company:
    ABM Therap
    Drug class:
    CDK8 inhibitor
    Related drugs:
    Associations

    News

    Trials
    over1year
    A potent and selective CDK8 inhibitor ABM-3249 with excellent efficacies in multiple in vivo cancer models (AACR 2023)
    It also showed an efficacy in a murine colon cancer B16F10 metastasis model. In addition, ABM-3249 displayed a good safety margin in a preliminary tox screen in rodents.
    Preclinical • PD(L)-1 Biomarker • IO biomarker
    |
    STAT1 (Signal Transducer And Activator Of Transcription 1)
    |
    ABM-3249